Equip WNV (previously Duvaxyn WNV)
vaccine to aid in prevention of West Nile virus
Table of contents
Overview
This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Equip WNV (previously Duvaxyn WNV)
|
Agency product number |
EMEA/V/C/000137
|
Active substance |
inactivated West Nile virus, strain VM-2
|
International non-proprietary name (INN) or common name |
vaccine to aid in prevention of West Nile virus
|
Species |
Horses
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI05AA10
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zoetis Belgium SA
|
Revision |
13
|
Date of issue of marketing authorisation valid throughout the European Union |
21/11/2008
|
Contact address |
Rue Laid Burniat 1 |
Product information
23/03/2017 Equip WNV (previously Duvaxyn WNV) - EMEA/V/C/000137 - IG/0747
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for equidae
Therapeutic indication
For the active immunisation of horses of six months of age or older against West-Nile-virus disease by reducing the number of viraemic horses.